{"id":172103,"name":"VERTEX PHARMACEUTICALS INCORPORATED","slug":"vertex-pharmaceuticals-incorporated","state":"MA","description":"Global biotechnology company","totalSpending":1250000,"filings":25,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":150000},{"year":2020,"income":150000},{"year":2021,"income":200000},{"year":2022,"income":200000},{"year":2024,"income":150000},{"year":2025,"income":200000}],"firms":["STANTON PARK GROUP"],"lobbyists":["JAMES DERDERIAN","ERIN STRAWN","VALERIE HENRY","EMILY SHETTY","SARAH HAMLETT","JOSEPH RACHINSKY","ANDREA BERGMAN","BRYAN WELLS","AISLING MCDONOUGH"],"issues":["HCR"],"sampleDescriptions":["issues related to rare and orphan disease therapeutics; issues related to FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; promoting reimbursement policies that protect patient access to pharmaceuticals; reauthorization of the Prescription Drug User Fee Amendments (PDUFA); CHIP reauthorization\norphan drug provisions of HR 1, Tax Cuts and Jobs Act","issues related to rare and orphan disease therapeutics; issues related to FDA regulatory pathways for pharmaceuticals; awareness of cystic fibrosis; promoting reimbursement policies that protect patient access to pharmaceuticals; reauthorization of the Prescription Drug User Fee Amendments (PDUFA); CHIP reauthorization\norphan drug tax credit, and orphan drug provisions of HR 1, Tax Cuts and Jobs Act\nIssues related to access to rare and orphan disease therapeutics under the enactment of ACA; Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing.","Access to rare and orphan disease therapeutics;  FDA regulatory pathways for pharmaceuticals; pharmaceutical pricing; awareness of cystic fibrosis; promoting reimbursement policies that protect patient access to pharmaceuticals;","Patient access to rare and orphan disease therapeutics; \nFDA regulatory pathways for pharmaceuticals; \nAwareness of Cystic Fibrosis","Patient access to rare and orphan disease therapeutics; \nFDA regulatory pathways for pharmaceuticals; \nAwareness of Cystic Fibrosis and Sickle Cell Disease","Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease","Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines;","Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 7142 and S. 3832"],"years":[2018,2019,2020,2021,2022,2024,2025]}